PG
SMMT icon

Proffitt & Goodson’s Summit Therapeutics SMMT Stock Holding History

Proffitt & Goodson’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-315
Closed -$6.7K – 449
2025
Q2 		$6.7K Buy
315
+100
+47% +$2.28K ﹤0.01% 221
2025
Q1 		$4.15K Buy
+215
New +$4.31K ﹤0.01% 229

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Proffitt & Goodson's SMMT Position: Q3 2025 in Review

Proffitt & Goodson sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 315 shares — an estimated $6.7K sold.

Proffitt & Goodson first reported a position in SMMT in Q1 2025 and held it in 2 quarters. The position peaked at $6.7K in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Proffitt & Goodson reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Proffitt & Goodson sold 315 Summit Therapeutics shares in Q3 2025, an estimated $6.7K.
  • Proffitt & Goodson first reported a position in Summit Therapeutics in Q1 2025 and held it in 2 quarters.
  • Proffitt & Goodson's Summit Therapeutics position peaked at $6.7K in Q2 2025.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Proffitt & Goodson's 13F filing for Q3 2025, filed 21 Oct 2025.